The FDA's Pharmacy Compounding Advisory Committee meets today — July 23 — at the agency's White Oak Campus in Silver Spring, Maryland, to vote on whether seven peptide compounds should be available through licensed compounding pharmacies. Wellness clinics and online vendors sell the compounds — BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon — for claimed benefits ranging from gut healing to sleep and longevity. The committee's vote is advisory, not binding. FDA's own staff reviewed all seven before the hearing and recommended against adding any of them to the official list. HHS Secretary Robert F. Kennedy Jr., who leads the Make America Healthy Again movement, has personally championed these compounds. HHS appointed eight of the twelve panelists just 24 days ago, and all but one have financial ties to businesses that sell or administer these same peptides.

1. Access First (HHS Secretary Kennedy, patient advocates, compounding pharmacies)

These compounds are already in use — a legal compounding pathway makes them safer, not more dangerous.

Over 95% of nearly 1,900 public comments supported preserving access. Patients are already using these compounds, and right now online vendors with no FDA oversight, no dose standardization, and no traceability are supplying them.

Kennedy says the compounds felt effective — he's used them himself. MAHA argues the FDA has been blocking legitimate treatments. This hearing is a chance to bring compounded versions under licensed pharmacy oversight. Rep. Diana Harshbarger (R-TN) wrote to Kennedy in 2025 pushing him to relax restrictions on six of these same peptides.

Of the seven candidates, BPC-157 has the most human trial data. Researchers tested it under code PL-14736 in an ulcerative colitis trial — thin, but real data. Pro-access advocates say that's enough of a foundation to let compounding pharmacies prepare it for patients with prescriptions, under a doctor's supervision, rather than leaving them to source it from gray-market vendors.

2. The Data Isn't There (ITIF, FDA staff, Forbes contributor Omer Awan)

Four of these seven compounds have no human safety data at all. The other three barely do.

FDA's own review team rejected every compound before today's hearing. The agency's briefing documented "scant high-quality randomized controlled human trials" for BPC-157 and "no human trial to date has shown it to be effective" for TB-500. This is the agency's career scientists recommending no, not an outside critic.

BPC-157 and TB-500 have been potentially linked to cancer in preclinical work. BPC-157 promotes angiogenesis — the formation of new blood vessels — which could theoretically accelerate tumor growth in people with undetected early-stage cancer. The FDA placed BPC-157 in Category 2 of unsafe compounding substances in 2023 because of immune reactions, peptide impurities, and missing safety data.

These compounds mostly come from a Chinese gray market, according to ITIF researchers Meghan Ostertag and Katie Kortbein, who published their analysis the day before today's hearing. Some of those gray-market suppliers have histories of illegal fentanyl precursor production. Independent lab tests have also found dangerous heavy metals in black-market peptide products. Ostertag and Kortbein pointed to a 15-fold increase in poison control calls linked to compounded GLP-1 drugs — warning that looser oversight of compounded peptides could produce the same result. Forbes contributor Omer Awan, writing July 21, put it plainly: "Popularity is not the same as evidence."

3. The Panel Can't Be Trusted (Owais Durrani, FDA career officials, investigative press)

A panel of sellers can't make a credible recommendation about what they sell.

Eight of twelve panelists sell or administer these compounds professionally. That's a departure from how FDA has historically composed these panels, which typically draw from academic researchers with no commercial stake. Gabriel Alizaidy, MD, who runs a peptide consultation practice, charges $500 per session. Haleem Mohammed, MD is CMO of Gameday Men's Health, a chain of Florida clinics selling peptides. Robert Harshbarger III, PharmD is a Tennessee state senator and compounding pharmacist whose mother lobbied Kennedy to loosen these same restrictions.

HHS says a regulatory exception makes the conflicts acceptable. The "broad sector interests" exception exists for panelists with general industry familiarity, not direct commercial entanglement. FDA officials raised internal concerns that these appointees "may have significant commercial conflicts of interest" before HHS finalized the panel. After the conflict criticism went public, HHS added more panelists, but the majority with industry ties remained.

People who profit from a decision shouldn't make it. Owais Durrani, DO, an emergency medicine physician, put it plainly: "when a majority of new appointees have direct financial or clinical ties to peptide-selling businesses, that's a structural conflict-of-interest problem." This vote sets a precedent — if an administration has a policy preference, it can stack advisory committees to match.

Where This Lands

The PCAC votes today, but the vote is advisory — whatever it recommends, FDA leadership still decides whether to start formal rulemaking, and FDA would need 6–18 months before any change reaches compounding pharmacies. The pro-access camp says bringing these compounds under pharmacy oversight is safer than the gray market that currently supplies them. The science skeptics say there's no human safety data to justify it, and two of the compounds carry preclinical cancer flags nobody has resolved. The process critics say none of that matters until the panel itself has no financial stake in the outcome.

Sources